Re: From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection
posted on
May 11, 2019 05:16PM
Bear – I never cease to be amazed at the depth of your knowledge in all of this. I’m guessing that this field is or was directly related to your profession/career, but I’ll leave my guesswork there so no need to respond to my assumptions in that regard. Anyway, I think that I speak for all of us on this board that we are extremely appreciative of your willingness to share that knowledge, and I’m sure that appreciation has been expressed many times by others long before I came on board.
Clearly most of us are optimistic (or at least cautiously optimistic) as regards the outcome of this trial, and the reasons for that optimism have been documented and discussed many times in prior posts (i.e., Phase 2 results, Shareholder confidence, safety, etc.). Nevertheless, based on your clear expertise in this whole field, would you be willing to share other reasons (if any) as to why you think this trial just might be successful?
I suppose you could simply refer me to many of your posts as evidence as why you believe being long on RVX is a good bet, but I’m just wondering if there something else related to this P3 trial specifically that might help to inspire your confidence. If you’ve been asked that before, or if your overall level optimism is based on the same reasons that have already been articulated, my apologies in advance.